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Abstract
Objectives: Several small studies indicate the sulphonamide component of the drug 
sulfasalazine lowers HbA1c. We investigated reduction of HbA1c following incident 
prescription of sulfasalazine and related aminosalicylates, lacking the sulphonamide 
group, in an observational cohort.
Research Design and Methods: Individuals in the Scottish Care Information 
Diabetes Collaboration (SCI-Diabetes) with type 2 diabetes and incident prescrip-
tion for an aminosalicylate drug (sulfasalazine, mesalazine, olsalazine or balsalazide) 
were identified. Baseline and 6-month HbA1c were required for eligibility, to calcu-
late HbA1c response. To investigate association with haemolysis, change in compo-
nents of full blood count was assessed. Paired t-tests compared difference in baseline 
and treatment HbA1c measures and other clinical variables.
Results: In all, 113 individuals treated with sulfasalazine and 103 with mesalazine 
(lacking the sulphonamide group) were eligible, with no eligible individuals treated 
with olsalazine or balsalazide. Baseline characteristics were similar. Mean (SD) HbA1c 
reduction at 6 months was −9 ± 16 mmol/mol (−0.9 ± 1.4%) (p < 0.0001) in those 
taking sulfasalazine with no reduction in those taking mesalazine (2 ± 16 mmol/mol 
(0.2 ± 1.4%). Sulfasalazine but not mesalazine was associated with a mean (SD) in-
crease in mean cell volume of 3.7 ± 5.6 fl (p < 0.0001) and decrease in red cell count 
of −0.2 ± 0.4 × 10−12/L (p < 0.0001).
Conclusions: In this observational, population-based study, sulfasalazine initiation 
was associated with a 6-month reduction in HbA1c. This correlated with haematologi-
cal changes suggesting haemolytic effects of sulfasalazine. Haemolysis is proposed 
to contribute to HbA1c lowering through the sulphonamide pharmacophore. This sug-
gests that HbA1c is not a reliable measure of glycaemia in individuals prescribed 
sulfasalazine.
K E Y W O R D S
Sulfasalazine, HbA1c, type 2 diabetes, glucose, sulphonamide, haemolysis
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1 |  INTRODUCTION
HbA1c testing has a significant role in management of dia-
betes because it gives an average indication of glycaemic 
control, avoiding day-to-day variations evident in glucose 
monitoring.1 In addition, HbA1c is a strong predictor of risk 
for development of diabetes-related complications,2 as well 
as being a cornerstone of glycaemic control targets and diag-
nosis of diabetes in national and international guidelines.3,4 
Haematological abnormalities including haemolytic anae-
mias, haemoglobinopathies, splenomegaly, blood loss/trans-
fusion and chronic liver disease are known to interfere with 
the accuracy of the HbA1c test.
5,6 However, there are few 
large-scale studies examining changes in HbA1c following 
incident drug treatment. Previously, the sulphonamide drugs 
dapsone, sulfamethoxazole and sulfasalazine have been re-
ported to lower HbA1c in case reports and case series.
7–13 One 
study attributed the effect of sulfasalazine on HbA1c to glu-
cose lowering13; however, most other studies attribute lower-
ing of HbA1c to haematological changes in dapsone
7,8,12 and 
sulfasalazine-treated individuals.7,12 Consistent with a ‘false’ 
lowering of HbA1c, measures of glucose and fructosamine, 
which is an additional measure of long-term glucose control, 
were unaffected by these drugs.7,9,11,12 Previous work sug-
gests that even mild, subclinical haemolysis that does not pro-
duce anaemia could have significant impacts on HbA1c.
7,11
Dapsone and sulfamethoxazole are prescribed only rarely 
in Scotland but in contrast sulfasalazine was prescribed 
112,765 times in the most recent year for which data were 
available, accounting for around 0.1% of all prescriptions, 
placing it in the top 10% of drugs prescribed14 in a population 
of just over five million people. In the current study, we have 
compared the effects of sulfasalazine and related 5-aminosa-
licylate (5-ASA) drugs on HbA1c. Sulfasalazine was the first 
ASA drug effective in inflammatory bowel disease (IBD), a 
term mainly used to describe Crohn's disease and ulcerative 
colitis. Sulfasalazine consists of 5-ASA joined with a sul-
phonamide group by a diazo bond (see Figure 1). The action 
of sulfasalazine in IBD relies on the diazo bond being cleaved 
in the colon, releasing the 5-ASA (reviewed in15). The 5-ASA 
component is poorly absorbed from the gastrointestinal tract, 
reaching its highest concentration in the colon and rectum. 
The sulphonamide moiety is well absorbed from the gut; 
systemic absorption of the sulphonamide moiety is likely to 
cause the classical adverse effects of sulfasalazine such as: 
blood dyscrasias, hypersensitivity reactions and infertility in 
men, as well as more common effects such as headaches and 
nausea.15,16 These adverse effects often result in difficulty ti-
trating the drug to a high enough dose for therapeutic anti-in-
flammatory effect of the 5-ASA.15
Further therapies were developed with the aim of mak-
ing the therapy more targeted to avoid sulfasalazine's side 
effects.17 The development of 5-ASA drugs lacking the 
sulphonamide group eliminated the side effects associated 
with sulfasalazine.15 Oral 5-ASA on its own is not an effec-
tive therapy as the drug is not concentrated in the distal gut. 
Newer drugs such as mesalazine, balsalazide and olsalazine 
release the active compound when the drug reaches the dis-
tal small bowel area, allowing the benefits of 5-ASA in IBD 
without the systemic adverse side effects of sulfasalazine.15
The aim of this study was to analyse the association of 
aminosalicylate drugs sulfasalazine, mesalazine, olsalazine 
and balsalazide on HbA1c in individuals with type 2 diabetes. 
What is already known about the subject?
• In case reports and case series, sulphonamide-
based drugs (including sulfa-antibiotics and 
dapsone) have been associated with reduction of 
HbA1c.
• Haemolytic effects of the drugs have been sug-
gested to underlie this effect.
What has this study found?
• Sulfasalazine is associated with HbA1c lowering.
• This effect is correlated with haematological 
changes consistent with haemolysis.
What are the clinical implications of the study?
• HbA1c may not be a reliable marker of glycaemia 
in individuals using drugs which cause haemoly-
sis. These groups may need to employ different 
glycaemic monitoring tools to prevent diabetes-
related complications. In these patients, HbA1c 
may not be a reliable diagnostic tool in type 2 
diabetes.
F I G U R E  1  Structure of sulfasalazine molecule in comparison to 
mesalazine molecule.24 Demonstrates the difference between these two 
drugs, in particular the sulphonamide, which in sulfasalazine only is 
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Based on previous case report/series evidence, we hypothe-
sised that sulfasalazine but not mesalazine, olsalazine or bal-
salazide, would lower HbA1c. In addition, we investigated the 
effect of these drugs on markers of haemolysis, including full 
blood count–red blood cells (RBC), mean cell haemoglobin 
(MCH) and haematocrit (HCT).
2 |  MATERIALS AND METHODS
2.1 | Data source & linkage
An observational cohort study was performed using compre-
hensive electronic medical records. Individuals with type 2 
diabetes in Tayside and Fife were identified from The Scottish 
Care Information-Diabetes Collaboration (SCI-Diabetes) and 
linked to clinical, laboratory and encashed prescription data-
sets. Data were collected and integrated by the Healthcare 
Informatics Centre (HIC) of University of Dundee, conform-
ing to ISO27001. This is a HIC project using anonymised 
data in line with HIC standard operating procedures and has 
Caldicott approval. Data linkage was through the Community 
Health Index number which is used widely in the NHS with 
over 99% accuracy for individuals with diabetes in Scotland.
2.2 | Study population
Complete prescribing data for aminosalicylates (defined as 
British National Formulary chapter 1.5.1) were available 
from 1st January 2005 and 1st January 2009, in Tayside and 
Fife, respectively, until 30th April 2017. All users of sul-
fasalazine, mesalazine, balsalazide and/ or olsalazine within 
the study period were identified. To be eligible for the study, 
all individuals must have received no prescriptions for ami-
nosalicylates in the calendar year 2005 and 2009 for Tayside 
and Fife, respectively, and could thus be considered treat-
ment naïve. Individuals whose first prescription was prior 
to diabetes diagnosis were also excluded. Therefore, the 
study population was defined as individuals with an incident 
prescription (a first prescription occurring in the specified 
time period) of sulfasalazine, mesalazine, balsalazide and/ 
or olsalazine on or after 1st January 2006 in Tayside or 1st 
January 2010 in Fife and after diagnosis of type 2 diabetes.
2.3 | Definition of HbA1c response and other 
clinical variables
Baseline HbA1c was defined as closest measure between 
6 months prior and 7 days after drug start date. The 6-month 
treatment HbA1c measure was defined as the measure closest 
to 6 months after drug start date but within a 3- to 9-month 
window. Although results are largely focused on 6-month re-
sponse, a 1-year treatment HbA1c measure was also defined as 
the measure closest to 1 year after drug start date but within a 
9- to 15-month window. HbA1c response was calculated as the 
difference between the baseline and treatment HbA1c. For in-
clusion in the study, individuals were required to have a base-
line and treatment measure to allow response to be assessed.
Baseline BMI, biochemical and haematological variables 
were defined as the closest measure between 1 year prior and 
7 days after drug start date. Treatment BMI, biochemical and 
haematological variables were defined as measures closest 
to 6 months in a 3- to 12-month window. These results were 
solely examined for a 6-month response. Individuals were 
required to have both a baseline and treatment measure for 
the stated variables, allowing for change in study period to 
be assessed.
2.4 | Study population derivation
A detailed flow chart of the study population is presented 
in Figure 2. There were 1046 individuals with an incident 
5-ASA prescription during the study period; 523 individuals 
treated with sulfasalazine, 506 treated with mesalazine, 53 
treated with balsalazide and 11 treated with olsalazine (some 
individuals had prescriptions for more than one of the drugs 
during the study period, hence the total is 1093).
A total of 305 and 255 individuals were eligible for anal-
ysis in the sulfasalazine and mesalazine groups, respectively. 
Due to very small numbers in the olsalazine and balsalazide 
groups, these drugs were excluded from the study. Of the 305 
individuals in the sulfasalazine group, 113 (37%) had a base-
line and 6-month HbA1c measure, and of the 255 individu-
als in the mesalazine group, 103 (40%) had a baseline and 
6-month HbA1c measure.
2.5 | Covariates
Individual characteristics of interest at baseline were gender, 
health board (Fife or Tayside), age at first prescription, age 
at type 2 diabetes diagnosis, HbA1c, BMI, bilirubin, RBC, 
MCH, HCT, haemoglobin (Hb) and mean cell corpuscular 
volume (MCV).
2.6 | Co-prescribing
Co-prescribed drugs which could alter HbA1c were identified 
from an initial list of all co-prescribed drugs. These drugs in-
cluded hydroxychloroquine, opiates, steroids, non-steroidal 
anti-inflammatory drugs (NSAIDs), methotrexate, folic acid, 
iron supplements and diabetes treatment.
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2.7 | Anaemia definition
Mild anaemia was defined as haemoglobin below 12 g/dl for 
women and below 13 g/dl for men, and moderate anaemia 
was defined as below 11 g/dl for both men and women, based 
on World Health Organisation (WHO) definitions.
2.8 | Statistical analyses
Comparisons of baseline characteristics and co-pre-
scribing frequency by drug group were by t-test for 
continuous variables and Chi-square test for categorical 
variables.
F I G U R E  2  Schematic flow chart demonstrating derivation of study population. The number of included is illustrated in each box, with number 
excluded represented with the arrows
N = 1,046 
Sulfasalazine Mesalazine Balsalazide Olsalazine 
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Paired t-tests were used to compare the difference in 
baseline and treatment measures of HbA1c and other clin-
ical variables. All analyses were performed using SAS 9.4 
and a p value of <0.05 considered statistically significant. 
No adjustment was made for multiplicity of statistical tests. 
Scatter graphs and Pearson correlation coefficients were used 
to identify linear relationships between significant haemato-
logical changes (MCV, MCH, RBC) and HbA1c change at 
6 months.
2.9 | Sensitivity analyses
Individuals in the sulfasalazine group taking relevant co-pre-
scribed drugs and anaemic individuals were removed from 
the study population and the HbA1C results re-analysed. In 
addition, statistically significant changes in haematologi-
cal variables were analysed for any correlation with HbA1c 
response.
3 |  RESULTS
3.1 | Baseline characteristics of the 
sulfasalazine and control group
There were a total of 113 eligible individuals in the sulfasala-
zine group and 103 in the mesalazine group (control group). 
A comparison of the two drug groups at baseline is presented 
in Table 1. Importantly, there was no statistically significant 
difference between the groups in baseline HbA1c or any of 
the variables tested.
The frequency of drugs co-prescribed during the study pe-
riod that may affect HbA1c are presented in Table 2. Drugs 
exhibiting statistically significant differences in prescribing 
between drug groups were as follows: methotrexate, hydroxy-
chloroquine, opiates, non-steroidal anti-inflammatory drugs 
and folic acid, which were each prescribed more commonly 
in the sulfasalazine cohort. The sulfasalazine group were pre-
scribed less anti-diabetic drugs with 50% on diet or monother-
apy treatment compared with 30% of the mesalazine group.
3.2 | HbA1c response and haematological 
responses in the sulfasalazine group
Initiation of sulfasalazine was associated with a mean (SD) 
HbA1c reduction of −9  ±  16  mmol/mol (−0.9  ±  1.4%) 
(p < 0.0001) in a 6-month period (Table 3). HbA1c remained 
lowered by −6 ± 16 mmol/mol (−0.5 ± 1.5%) (p = 0.004) after 
1  year. In contrast, initiation of mesalazine was associated 
with a non-significant increase in HbA1c by 2 ± 16 mmol/
mol (−0.2 ± 1.4%) (p = 0.23). HbA1c response 1 year from 
incident mesalazine prescription was 0  ±  18  mmol/mol 
(0 ± 1.6%) (p = 0.99). Other statistically significant changes 
in the sulfasalazine group were decreased RBC and increased 
T A B L E  1  Comparison of baseline characteristics. Data are mean (SD) or N(%); Comparisons are by t-test for continuous variables and Chi-
square test for categorical variables
Variable Sulfasalazine N Mesalazine N
p 
Value
Gender Men Women 113 Men Women 103 0.14
59 (52%) 54 (48%) 64 (62%) 39 (38%)
Location Fife Tayside 113 Fife Tayside 103 0.41
49 (43%) 64 (57%) 39 (38%) 64 (62%)
Age (years) 66.4 ± 11.5 113 65.6 ± 12.5 103 0.61
Age at type 2 diabetes 
diagnosis (years)
58.0 ± 12.2 113 58.2 ± 12.7 103 0.93
HbA1c (mmol/mol/%) 57 ± 17 (7.4 ± 1.6) 113 61 ± 18 (7.7 ± 1.6) 103 0.16
BMI (kg/m2) 32.3 ± 6.5 105 31.6 ± 6.4 97 0.45
Bilirubin (µmol/L) 7.8 ± 5.4 111 8.9 ± 4.7 103 0.14
RBC (×1012/L) 4.4 ± 0.5 112 4.4 ± 0.6 97 0.49
MCH (pg) 29.2 ± 2.4 112 29.7 ± 2.3 97 0.05
HCT (L/L) 0.4 ± 0.04 112 0.4 ± 0.05 97 0.29
Hb (g/dl) 12.8 ± 1.6 112 13.2 ± 2.0 97 0.06
MCV(fl) 90.4 ± 6.2 112 90.9 ± 5.3 96 0.56
Mild anaemia 50 (45%) 112 35 (36%) 97 0.21
Moderate anaemia 15 (13%) 112 13 (13%) 97 0.99
Percentages are presented in italics.
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MCH and MCV levels. There were no significant changes 
in the mesalazine group. Figure 3 demonstrates the correla-
tion observed between these haematological factors and the 
HbA1c response. The HbA1c response was correlated with 
significantly increased MCV (p = 0.01) and significantly de-
creased RBC (p = 0.01). A non-statistically significant cor-
relation with decreasing MCH (p = 0.13) was also observed.
3.3 | Impact of co-prescribing and anaemia
We performed sensitivity analyses on the sulfasalazine group, 
with individuals on specific co-prescribed drugs excluded 
(Table 4). The lowering effect of sulfasalazine on HbA1c was 
still evident despite the removal of these individuals. Further 
sensitivity analysis excluded anaemic individuals from the 
cohort (Table 5). This also had little impact on the HbA1c 
response.
4 |  DISCUSSION
4.1 | Principal findings
In this study, we analysed data from 216 individuals with 
type 2 diabetes, to study effects of the sulphonamide group 
of the drug sulfasalazine on HbA1c. Mesalazine acted as 
a control, as it lacks a sulphonamide group. There was no 
significant difference in baseline measurements including 
HbA1c between the two groups. The principal finding is that 
sulfasalazine introduction was associated with a statistically 
significant and clinically important decrease in HbA1c, while 
mesalazine introduction was not. This finding suggests that 
the effect in the sulfasalazine-treated group depends on the 
systemically available sulphonamide moiety, which is absent 
in mesalazine, rather than being an effect of the gut-confined 
5-ASA. The HbA1c reduction was still evident in sensitiv-
ity analyses which excluded possible effects of co-prescribed 
drugs, including diabetes medications.
Our study suggests that haemolysis mediates the effect of 
sulfasalazine on HbA1c. Haemolysis is a known adverse effect 
of sulphonamide drugs.18,19 Sulphonamide-induced haemoly-
sis was first described in the early 1900 s.18 Significantly in-
creased MCV, MCH and a significantly decreased RBC with 
incident sulfasalazine treatment are suggestive of macrocy-
tosis20 and possibly mild haemolysis. These changes were 
correlated with HbA1c lowering (as shown in Figure 3), sug-
gesting that they may be mechanistically linked. Haemolysis 
T A B L E  2  Comparison of frequency of co-prescribed drugs. Data 






Hydroxychloroquine 40 (35%) 0 (0%) <0.0001
Opiates 100 (88%) 66 (64%) <0.0001
Steroids 51(45%) 41 (40%) 0.43
NSAIDs 50 (44%) 16 (16%) <0.0001
Methotrexate 61(54%) 1 (1%) <0.0001
Folic Acid 62 (55%) 6 (6%) <0.0001
Iron Supplements 29 (26%) 27 (26%) 0.89
Anti-diabetic therapy group:
Diet treated 25 (22%) 16 (16%) 0.02
Monotherapy 32 (28%) 15 (15%)
Dual therapy 37 (33%) 44 (43%)
Insulin therapy 19 (17%) 28 (27%)
Percentages are presented in italics.
T A B L E  3  Changes in clinical measurements during the study period. Data are mean (SD) from paired t-tests comparing treatment – baseline 
measurement
Sulfasalazine Mesalazine
N Variable change p Value N Variable change p Value
6 month HbA1c change (mmol/
mol/%)
113 −9 ± 16 (−0.9 ± 1.4) <0.0001 103 +2 ± 16 (+0.2 ± 1.4) 0.23
One year HbA1c change 
(mmol/mol/%)
72 −6 ± 16 (−0.5 ± 1.5) 0.004 79 0 ± 18 (0 ± 1.6) 0.99
BMI (kg/m2) 94 −0.3 ± 2.0 0.13 83 −0.2 ± 1.8 0.46
Bilirubin (µmol/L) 111 −0.2 ± 5.7 0.70 101 +0.4 ± 3.2 0.21
RBC (x1012/L) 112 −0.2 ± 0.4 <0.0001 97 +0.04 ± 0.4 0.29
MCH (pg) 112 +1.2 ± 2.1 <0.0001 95 −0.2 ± 1.6 0.35
HCT (L/L) 112 −0.01 ± 0.04 0.15 95 +0.003 ± 0.04 0.42
Hb (g/dL) 112 −0.2 ± 1.3 0.21 95 +0.03 ± 1.3 0.79
MCV (fL) 112 +3.7 ± 5.6 <0.0001 94 −0.2 ± 4.2 0.72
Percentages are presented in italics.
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may lower HbA1c by shortening lifespan of red blood cells. 
With an increase in red blood cell turnover, the period of time 
which the haemoglobin is exposed to blood glucose will be 
shorter, reducing the degree of glycation. This presents a pos-
sible limitation of HbA1c as a glycaemic control marker in 
this cohort of people, as well as suggesting that HbA1c is not 
a reliable diagnostic tool in individuals taking sulfasalazine. 
Consistent with sulfasalazine inducing only a mild, subclini-
cal level of haemolysis,21 we did not detect an increase in the 
bilirubin levels in the blood, nor was there any significant 
change in haemoglobin levels. There is a well-established 
link between sulfasalazine use and megaloblastic anaemia,16 
which is associated with a decrease in cell turnover, allowing 
the red cell to have an increased exposure time to circulating 
glucose and ultimately increasing glycation of haemoglobin.6 
We investigated the possibility that megaloblastic anaemia 
could have masked an even more profound HbA1c effect in 
the sulfasalazine group but in sensitivity analysis, anaemia 
did not have a significant impact on the effect of sulfasalazine 
on HbA1c.
F I G U R E  3  Correlations between haematological variables and 
HbA1c. (A) Negative linear relationship between change of MCV 
and change in HbA1c (correlation coefficient −0.23 (p = 0.01)); (B) 
Negative linear relationship between change in MCH and change in 
HbA1c (correlation coefficient −0.14 (p = 0.13)); (C) Positive linear 








































































T A B L E  4  Changes in 6 month HbA1c in sulfasalazine group with 
individuals coprescribed specific drugs excluded. Data are mean (SD) 
from paired t-tests comparing treatment – baseline measurement drugs



























Percentages are presented in italics.
T A B L E  5  Changes in 6-month HbA1c in sulfasalazine group with 
individuals with anaemia excluded. Data are mean (SD) from paired 












Percentages are presented in italics.
aMild anaemia was defined as haemoglobin below 12g/dL for women and below 
13g/dL for men. 
bModerate anaemia was defined as below 11g/dL for both men and women. 
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Further work will be required to determine whether other 
sulphonamide drugs, particularly those which are very com-
monly prescribed, such as furosemide, elicit similar effects 
on HbA1c. In addition, other drugs with different structure 
are known to affect haematological components22 and some 
of these, such as thiazides, are commonly prescribed as well; 
however, there has been little investigation of effects of these 
drugs on the HbA1c test either. Alongside the suggestion that 
subtle abnormalities of red cells (with or without anaemia, 
through various mechanisms) are enough to have a signif-
icant impact on HbA1c,
23 further work should examine in 
depth the link between red cell component abnormality and 
HbA1c.
4.2 | Limitations of this study
Our study was observational and consequently we cannot ex-
clude that differences between the drug groups may owe to 
individual characteristics, particularly their disease profile. 
Mesalazine is prescribed only in IBD, whereas the systemic 
anti-inflammatory effects of sulfasalazine have led to its use 
in rheumatoid arthritis as well. In addition, there were some 
factors that this study could not account for, such as effects of 
short-term inflammatory or comorbid conditions, subsequent 
hospital admissions, medication compliance and their effects 
on HbA1c. The study was also limited to the data available; 
therefore, some factors could not be analysed. These factors 
could have helped us to study the mechanism behind the sul-
fasalazine effect on HbA1c further, they include vitamin B12 
and folate levels, insulin, C-peptide and other markers of 
haemolysis such as reticulocyte count, lactate dehydrogenase 
and haptoglobin. In addition, oral glucose tolerance testing, 
fasting plasma glucose levels and fructosamine measure-
ments were not available as alternative measures of short-
term and long-term glucose control.
Despite these limitations, baseline characteristics were 
broadly similar between the cohorts suggestive of minimal 
ascertainment bias, and the use of sensitivity analyses also 
found little evidence of other confounding factors that could 
have had an influence on the final HbA1c response.
We do not exclude possible mechanisms other than hae-
molysis underlying the effect of sulfasalazine on HbA1c. 
Sulphonamides are structurally reminiscent, for example, of 
sulfonylureas and some evidence suggests they may induce 
insulin secretion.24
5 |  SUMMARY
In conclusion, we have used analysis of a cohort of indi-
viduals with type 2 diabetes in Tayside and Fife to replicate 
at a population level, evidence from several much smaller 
studies suggesting that sulfasalazine mediates a clinically 
relevant suppression of HbA1c. The effect of sulfasalazine 
on HbA1c is likely to be mediated by the sulphonamide moi-
ety of the drug, through a mechanism involving haemolysis. 
These findings suggest that HbA1c is not a reliable measure 
of glycaemia and therefore should not be used for diagnosis 
and monitoring of type 2 diabetes in individuals prescribed 
sulfasalazine.
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